[go: up one dir, main page]

CO6690116A1 - Nueva asociación entre la 4-[3-(cis-hexahidrociclopenta[c]pirrol -2(1h)-il]propoxi]benzamida y un antagonista de los receptores nmda y las composiciones famacéuticas que las contienen - Google Patents

Nueva asociación entre la 4-[3-(cis-hexahidrociclopenta[c]pirrol -2(1h)-il]propoxi]benzamida y un antagonista de los receptores nmda y las composiciones famacéuticas que las contienen

Info

Publication number
CO6690116A1
CO6690116A1 CO12221472A CO12221472A CO6690116A1 CO 6690116 A1 CO6690116 A1 CO 6690116A1 CO 12221472 A CO12221472 A CO 12221472A CO 12221472 A CO12221472 A CO 12221472A CO 6690116 A1 CO6690116 A1 CO 6690116A1
Authority
CO
Colombia
Prior art keywords
benzamide
propoxy
cis
hexahydrocyclopenta
pyrrole
Prior art date
Application number
CO12221472A
Other languages
English (en)
Inventor
Aurore Sors
Thibierge Caryn Trocme
Annette Merdes
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47682151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6690116(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CO6690116A1 publication Critical patent/CO6690116A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a una nueva asociación entre la 4-{3-[cis- hexahidrociclopenta[c]pirrol-2(1H)-iI]propoxi)benzamida, o una de sus sales de adición a un ácido o una base farmacéuticamente aceptable y un antagonista, la memantina, de los receptores NMDA para el tratamiento de los trastornos cognitivos asociadas al envejecimiento cerebral y a las enfermedades neurodegenerativas como el Alzheimér. En esta asociación la 4-{3-[cis-hexahidr-ociclopenta[c]pirrol-2(1H)-iI]propoxi)benzamida se utiliza en forma de un oxalato o de un hidrocloruro, a unas dosis de 2, 5 o 20 mg, y el antagonista en forma de hidrocloruro, a unas dosis de 10 o 20 mg, Además, estos compuestos pueden utilizarse con uno o varios excipientes farmacéuticamente aceptables para el tratamiento de estos trastornos. La formula de la 4-{3-[cis- hexahidrociclopenta[c]pirrol-2(1 H)-iI]propoxi)benzamida es la siguiente:
CO12221472A 2011-12-09 2012-12-06 Nueva asociación entre la 4-[3-(cis-hexahidrociclopenta[c]pirrol -2(1h)-il]propoxi]benzamida y un antagonista de los receptores nmda y las composiciones famacéuticas que las contienen CO6690116A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161568831P 2011-12-09 2011-12-09
FR1103777A FR2983732B1 (fr) 2011-12-09 2011-12-09 Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
CO6690116A1 true CO6690116A1 (es) 2013-06-17

Family

ID=47682151

Family Applications (2)

Application Number Title Priority Date Filing Date
CO12069442A CO6660080A1 (es) 2011-12-09 2012-04-27 Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmaceuticas que la contienen
CO12221472A CO6690116A1 (es) 2011-12-09 2012-12-06 Nueva asociación entre la 4-[3-(cis-hexahidrociclopenta[c]pirrol -2(1h)-il]propoxi]benzamida y un antagonista de los receptores nmda y las composiciones famacéuticas que las contienen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CO12069442A CO6660080A1 (es) 2011-12-09 2012-04-27 Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmaceuticas que la contienen

Country Status (28)

Country Link
US (2) US8921409B2 (es)
EP (1) EP2601942A1 (es)
JP (1) JP5591310B2 (es)
KR (1) KR101489670B1 (es)
CN (1) CN103157111B (es)
AP (1) AP3225A (es)
AR (1) AR089112A1 (es)
AU (1) AU2012258339A1 (es)
BR (1) BR102012031031A2 (es)
CA (1) CA2798549A1 (es)
CL (1) CL2012003437A1 (es)
CO (2) CO6660080A1 (es)
CR (1) CR20120608A (es)
EA (1) EA201201530A1 (es)
EC (1) ECSP12012329A (es)
FR (1) FR2983732B1 (es)
GT (1) GT201200329A (es)
MA (1) MA34867B1 (es)
MD (1) MD4348B1 (es)
MX (1) MX2012014184A (es)
NI (1) NI201200178A (es)
PE (1) PE20130813A1 (es)
PH (1) PH12012000378A1 (es)
SG (1) SG191494A1 (es)
TN (1) TN2012000563A1 (es)
TW (1) TWI457123B (es)
UY (1) UY34475A (es)
WO (1) WO2013083887A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3003466B1 (fr) * 2013-03-22 2015-08-07 Servier Lab Utilisation du 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide pour le traitement des douleurs neuropathiques
KR101484405B1 (ko) * 2013-08-14 2015-01-19 서울대학교산학협력단 Ｎｉｎｊｕｒｉｎ１ 결핍 유래의 강박증 예방 또는 치료용 약학적 조성물
GB201509134D0 (en) * 2015-05-28 2015-07-15 Electrophoretics Ltd Biomolecules involved in Alzheimer's disease
WO2017013496A1 (en) * 2015-07-22 2017-01-26 Anavex Life Sciences Corp. Enantiomers of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine (anavex2-73) and use thereof in the treatment of alzheimer's disease and other disorders modulated by the sigma 1 receptor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1509232E (pt) * 2002-05-31 2009-01-07 Lundbeck & Co As H Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
UA80055C2 (en) * 2003-05-27 2007-08-10 Forest Laboratories Combination of nmda-receptor antagonist and selective inhibitor of serotonin reuptake for a depression and other pscihiatric disorders treatment
EP1638560A1 (en) * 2003-06-20 2006-03-29 Eli Lilly And Company 3-aminopiperidines and 3-aminoquinuclidines as inhibitors of monoamine uptake
WO2005067908A2 (en) * 2004-01-05 2005-07-28 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of mild and mild-to-moderate alzheimer’s disease
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
EP1740172A4 (en) * 2004-03-19 2007-10-10 Axonyx Inc ACETYLCHOLINESTERASE INHIBITORS AND N-METHYL-D-ASPARTATE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DISORDER
FR2937119B1 (fr) 2008-10-15 2010-12-17 Air Liquide Procede de production d'energie et capture de co2
FR2937251B1 (fr) * 2008-10-16 2011-03-18 Servier Lab Utilisation du 4-{3-°hexahydrocyclopenta°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil
FR2953515B1 (fr) * 2009-12-09 2011-12-23 Servier Lab Nouveaux derives du type hexahydrocyclopenta[b]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PE20130813A1 (es) 2013-07-28
KR20130065602A (ko) 2013-06-19
TWI457123B (zh) 2014-10-21
CA2798549A1 (fr) 2013-06-09
TN2012000563A1 (fr) 2014-04-01
AP3225A (en) 2015-04-30
PH12012000378A1 (en) 2015-09-11
CO6660080A1 (es) 2013-04-30
JP2013121956A (ja) 2013-06-20
TW201334777A (zh) 2013-09-01
US20130150421A1 (en) 2013-06-13
CL2012003437A1 (es) 2014-01-24
CN103157111B (zh) 2015-02-11
FR2983732B1 (fr) 2013-11-22
FR2983732A1 (fr) 2013-06-14
CR20120608A (es) 2014-03-05
UY34475A (es) 2013-07-31
CN103157111A (zh) 2013-06-19
GT201200329A (es) 2014-03-14
WO2013083887A1 (fr) 2013-06-13
US8921409B2 (en) 2014-12-30
EA201201530A1 (ru) 2013-07-30
NZ604084A (en) 2014-07-25
ECSP12012329A (es) 2013-01-31
MA34867B1 (fr) 2014-02-01
AU2012258339A1 (en) 2013-06-27
MD4348B1 (ro) 2015-05-31
NI201200178A (es) 2013-05-13
SG191494A1 (en) 2013-07-31
JP5591310B2 (ja) 2014-09-17
WO2013083887A8 (fr) 2013-08-08
EP2601942A1 (fr) 2013-06-12
AP2012006607A0 (en) 2012-12-31
KR101489670B1 (ko) 2015-02-04
AR089112A1 (es) 2014-07-30
BR102012031031A2 (pt) 2013-10-29
US20150080448A1 (en) 2015-03-19
MX2012014184A (es) 2013-06-18

Similar Documents

Publication Publication Date Title
DOP2014000265A (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
EA201492281A1 (ru) Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
UY35612A (es) Compuestos de sulfonamida bicíclicos como inhibidores de los canales de sodio
JO3425B1 (ar) مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CL2012003178A1 (es) Compuestos derivados de heterociclos nitrogenados insaturados o sus sales farmaceuticamente aceptables, como inhibidores de pde10; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades tales como psicosis, enfermedad de parkinson, depresion, trastornos del humor y demencia.
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
MX2012013206A (es) Inhibidores de quinasa biciclica fusionada.
SI2875011T1 (en) 5-HT3 receptor antagonists
CR20140516A (es) Compuestos de pirazol sustituidos como antagonistas de lpar
CO6690116A1 (es) Nueva asociación entre la 4-[3-(cis-hexahidrociclopenta[c]pirrol -2(1h)-il]propoxi]benzamida y un antagonista de los receptores nmda y las composiciones famacéuticas que las contienen
AR086146A1 (es) Asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmaceuticas que la contienen
BR112015006454A8 (pt) derivados de etinila como moduladores de atividade de receptor de mglur5
MX2018007432A (es) Compuestos de dihidroquinolinsulfonamida de alquilo.
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
EA201692404A1 (ru) Пептиды, выполняющие роль агонистов окситоцина
CL2012001500A1 (es) Procedimiento de preparacion de hidrocloruro de 4-{3-[cis-hexahidrociclopenta [c]pirrol-2(1h)-il]propoxi}benzamida; formas cristalinas de la base libre y del hidrocloruro; compuestos intermediarios; composiciones farmaceuticas que los contienen; y su uso en el tratamiento de trastornos cognitivos y enfermedades neurodegenerativas.
CU20110093A7 (es) Pirrolidinas
PH12015500496A1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
BR112015002320A2 (pt) derivados de etinila como moduladores de atividade de receptor mglur5
MX2014000855A (es) Moduladores receptores de glucagon de quinolinilo.
AR077958A1 (es) Quinoxalinonas antagonistas de la hepcidina
CU20120167A7 (es) Nueva asociación entre la 4-{3-(cis-hexahidrociclopenta(c)pirrol-2(1h)-il)propoxi}benzamida y un antagonista de los receptores nmda y las composiciones farmacéuticas que la contienen
UA113991C2 (xx) 1-(1-метил-1h-піразол-4-іл)-n-((1r,5s,7s)-9-метил-3-окса-9-азабіцикло[3.3.1]-нонан-7-іл)-1h-індол-3-карбоксамід як антагоніст 5-ht3 рецептора